How Combination Therapies With JAK Inhibitors May Change MPN Treatment

Published on

Topics include: Treatments

Soon there will be multiple JAK2 inhibitor drugs on the market. Will they make a difference for polycythemia vera (PV) and essential thrombocythemia (ET) patients? And how significant are they in treating myelofibrosis? Leading European expert Dr. Francisco Cervantes talks about how this class of drugs may be used alone or in combination to improve MPN outcomes. Watch now.

View more programs featuring

Join Our Community Register for Events Read Our Latest Blog

Page last updated on April 26, 2017